Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Sentry Investment Management LLC

Sentry Investment Management LLC reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 9.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,189 shares of the medical research company’s stock after selling 343 shares during the period. Sentry Investment Management LLC’s holdings in Edwards Lifesciences were worth $243,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Advisors Asset Management Inc. boosted its position in Edwards Lifesciences by 0.3% during the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after purchasing an additional 117 shares during the period. Apollon Wealth Management LLC boosted its position in Edwards Lifesciences by 1.0% during the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock worth $1,033,000 after acquiring an additional 119 shares during the period. Geller Advisors LLC boosted its position in Edwards Lifesciences by 6.5% during the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock worth $231,000 after acquiring an additional 120 shares during the period. Legacy Wealth Asset Management LLC boosted its position in Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after acquiring an additional 134 shares during the period. Finally, KCM Investment Advisors LLC boosted its position in Edwards Lifesciences by 2.7% during the 1st quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock worth $635,000 after acquiring an additional 142 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have issued reports on EW. Mizuho boosted their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Oppenheimer boosted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Citigroup boosted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus upped their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a report on Wednesday, February 7th. Finally, Evercore ISI upped their price objective on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.73.

Insider Activity at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 194,004 shares of company stock valued at $17,166,254. Company insiders own 1.27% of the company’s stock.

Edwards Lifesciences Stock Up 1.0 %

Shares of Edwards Lifesciences stock opened at $90.06 on Wednesday. The stock’s fifty day moving average is $90.11 and its 200-day moving average is $78.07. The firm has a market capitalization of $54.21 billion, a PE ratio of 39.16, a price-to-earnings-growth ratio of 4.42 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.64 earnings per share. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.